<?xml version="1.0"?>


<!DOCTYPE rdf:RDF [
    <!ENTITY owl "http://www.w3.org/2002/07/owl#" >
    <!ENTITY obo "http://purl.obolibrary.org/obo/" >
    <!ENTITY dc "http://purl.org/dc/elements/1.1/" >
    <!ENTITY xsd "http://www.w3.org/2001/XMLSchema#" >
    <!ENTITY rdfs "http://www.w3.org/2000/01/rdf-schema#" >
    <!ENTITY rdf "http://www.w3.org/1999/02/22-rdf-syntax-ns#" >
    <!ENTITY oboInOwl "http://www.geneontology.org/formats/oboInOwl#" >
]>


<rdf:RDF xmlns="http://www.semanticweb.org/mathiasbrochhausen/ontologies/2014/9/untitled-ontology-25#"
     xml:base="http://www.semanticweb.org/mathiasbrochhausen/ontologies/2014/9/untitled-ontology-25"
     xmlns:dc="http://purl.org/dc/elements/1.1/"
     xmlns:obo="http://purl.obolibrary.org/obo/"
     xmlns:rdfs="http://www.w3.org/2000/01/rdf-schema#"
     xmlns:owl="http://www.w3.org/2002/07/owl#"
     xmlns:xsd="http://www.w3.org/2001/XMLSchema#"
     xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
     xmlns:oboInOwl="http://www.geneontology.org/formats/oboInOwl#">
    <owl:Ontology rdf:about="&obo;dideo/dev/dideo.owl">
        <rdfs:label xml:lang="en">DIDEO</rdfs:label>
        <rdfs:label xml:lang="en">Drug-drug Interaction and Drug-drug Interaction Evidence Ontology </rdfs:label>
        <dc:contributor xml:lang="en">Dan Malone</dc:contributor>
        <dc:contributor xml:lang="en">Jodi Schneider</dc:contributor>
        <dc:contributor xml:lang="en">Mathias Brochhausen</dc:contributor>
        <dc:contributor xml:lang="en">Philip E. Empey</dc:contributor>
        <dc:contributor xml:lang="en">Richard D. Boyce</dc:contributor>
        <dc:contributor xml:lang="en">William R. Hogan</dc:contributor>
        <owl:versionInfo xml:lang="en">development version 20115-01-02</owl:versionInfo>
        <owl:imports rdf:resource="&obo;iao/bfo2-transitional/iao.owl"/>
    </owl:Ontology>
    


    <!-- 
    ///////////////////////////////////////////////////////////////////////////////////////
    //
    // Annotation properties
    //
    ///////////////////////////////////////////////////////////////////////////////////////
     -->

    


    <!-- http://purl.obolibrary.org/obo/IAO_0000111 -->

    <rdf:Description rdf:about="&obo;IAO_0000111">
        <rdfs:label xml:lang="en">editor preferred label</rdfs:label>
        <rdfs:label>editor preferred term</rdfs:label>
        <rdfs:label xml:lang="en">editor preferred term</rdfs:label>
    </rdf:Description>
    


    <!-- http://purl.obolibrary.org/obo/IAO_0000112 -->

    <rdf:Description rdf:about="&obo;IAO_0000112">
        <rdfs:label xml:lang="en">example of usage</rdfs:label>
    </rdf:Description>
    


    <!-- http://purl.obolibrary.org/obo/IAO_0000114 -->

    <rdf:Description rdf:about="&obo;IAO_0000114">
        <rdfs:label xml:lang="en">has curation status</rdfs:label>
    </rdf:Description>
    


    <!-- http://purl.obolibrary.org/obo/IAO_0000115 -->

    <rdf:Description rdf:about="&obo;IAO_0000115">
        <rdfs:label rdf:datatype="&xsd;string">definition</rdfs:label>
        <rdfs:label rdf:datatype="&xsd;string">textual definition</rdfs:label>
        <rdfs:label>definition</rdfs:label>
        <rdfs:label xml:lang="en">definition</rdfs:label>
    </rdf:Description>
    


    <!-- http://purl.obolibrary.org/obo/IAO_0000116 -->

    <rdf:Description rdf:about="&obo;IAO_0000116">
        <rdfs:label xml:lang="en">editor note</rdfs:label>
    </rdf:Description>
    


    <!-- http://purl.obolibrary.org/obo/IAO_0000117 -->

    <rdf:Description rdf:about="&obo;IAO_0000117">
        <rdfs:label xml:lang="en">definition editor</rdfs:label>
        <rdfs:label xml:lang="en">term editor</rdfs:label>
    </rdf:Description>
    


    <!-- http://purl.obolibrary.org/obo/IAO_0000118 -->

    <rdf:Description rdf:about="&obo;IAO_0000118">
        <rdfs:label xml:lang="en">alternative term</rdfs:label>
    </rdf:Description>
    


    <!-- http://purl.obolibrary.org/obo/IAO_0000119 -->

    <rdf:Description rdf:about="&obo;IAO_0000119">
        <rdfs:label xml:lang="en">definition source</rdfs:label>
    </rdf:Description>
    


    <!-- http://purl.obolibrary.org/obo/IAO_0000136 -->

    <owl:AnnotationProperty rdf:about="&obo;IAO_0000136"/>
    


    <!-- http://purl.obolibrary.org/obo/IAO_0000232 -->

    <rdf:Description rdf:about="&obo;IAO_0000232">
        <rdfs:label xml:lang="en">curator note</rdfs:label>
    </rdf:Description>
    


    <!-- http://purl.obolibrary.org/obo/IAO_0000412 -->

    <rdf:Description rdf:about="&obo;IAO_0000412">
        <rdfs:label xml:lang="en">imported from</rdfs:label>
    </rdf:Description>
    


    <!-- http://purl.obolibrary.org/obo/OBI_0001847 -->

    <rdf:Description rdf:about="&obo;OBI_0001847">
        <rdfs:label xml:lang="en">ISA alternative term</rdfs:label>
    </rdf:Description>
    


    <!-- http://purl.obolibrary.org/obo/OBI_9991118 -->

    <rdf:Description rdf:about="&obo;OBI_9991118">
        <rdfs:label rdf:datatype="&xsd;string">IEDB alternative term</rdfs:label>
    </rdf:Description>
    


    <!-- http://www.geneontology.org/formats/oboInOwl#hasAlternativeId -->

    <owl:AnnotationProperty rdf:about="&oboInOwl;hasAlternativeId"/>
    


    <!-- http://www.geneontology.org/formats/oboInOwl#hasDbXref -->

    <owl:AnnotationProperty rdf:about="&oboInOwl;hasDbXref"/>
    


    <!-- http://www.geneontology.org/formats/oboInOwl#hasDefinition -->

    <owl:AnnotationProperty rdf:about="&oboInOwl;hasDefinition"/>
    


    <!-- http://www.geneontology.org/formats/oboInOwl#hasExactSynonym -->

    <owl:AnnotationProperty rdf:about="&oboInOwl;hasExactSynonym"/>
    


    <!-- http://www.geneontology.org/formats/oboInOwl#hasNarrowSynonym -->

    <owl:AnnotationProperty rdf:about="&oboInOwl;hasNarrowSynonym"/>
    


    <!-- http://www.geneontology.org/formats/oboInOwl#hasOBONamespace -->

    <owl:AnnotationProperty rdf:about="&oboInOwl;hasOBONamespace"/>
    


    <!-- http://www.geneontology.org/formats/oboInOwl#inSubset -->

    <owl:AnnotationProperty rdf:about="&oboInOwl;inSubset"/>
    


    <!-- http://www.w3.org/2000/01/rdf-schema#label -->

    <rdf:Description rdf:about="&rdfs;label">
        <rdfs:label>label</rdfs:label>
    </rdf:Description>
    


    <!-- 
    ///////////////////////////////////////////////////////////////////////////////////////
    //
    // Classes
    //
    ///////////////////////////////////////////////////////////////////////////////////////
     -->

    


    <!-- http://purl.obolibrary.org/obo/CHEBI_24431 -->

    <owl:Class rdf:about="&obo;CHEBI_24431">
        <rdfs:label xml:lang="en">chemical entities</rdfs:label>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/DIDEO_00000000 -->

    <owl:Class rdf:about="&obo;DIDEO_00000000">
        <rdfs:label xml:lang="en">potential drug drug interaction</rdfs:label>
        <rdfs:subClassOf rdf:resource="&obo;IAO_0000030"/>
        <rdfs:subClassOf>
            <owl:Class>
                <owl:intersectionOf rdf:parseType="Collection">
                    <owl:Restriction>
                        <owl:onProperty rdf:resource="&obo;IAO_0000709"/>
                        <owl:someValuesFrom rdf:resource="&obo;DIDEO_00000011"/>
                    </owl:Restriction>
                    <owl:Restriction>
                        <owl:onProperty rdf:resource="&obo;IAO_0000709"/>
                        <owl:someValuesFrom rdf:resource="&obo;DIDEO_00000014"/>
                    </owl:Restriction>
                </owl:intersectionOf>
            </owl:Class>
        </rdfs:subClassOf>
        <rdfs:subClassOf>
            <owl:Class>
                <owl:intersectionOf rdf:parseType="Collection">
                    <rdf:Description rdf:about="&obo;IAO_0000030"/>
                    <owl:Restriction>
                        <owl:onProperty rdf:resource="&obo;IAO_0000709"/>
                        <owl:someValuesFrom>
                            <owl:Class>
                                <owl:unionOf rdf:parseType="Collection">
                                    <rdf:Description rdf:about="&obo;DIDEO_00000002"/>
                                    <rdf:Description rdf:about="&obo;DIDEO_00000003"/>
                                    <rdf:Description rdf:about="&obo;DIDEO_00000004"/>
                                    <rdf:Description rdf:about="&obo;DIDEO_00000005"/>
                                </owl:unionOf>
                            </owl:Class>
                        </owl:someValuesFrom>
                    </owl:Restriction>
                </owl:intersectionOf>
            </owl:Class>
        </rdfs:subClassOf>
        <obo:IAO_0000115 xml:lang="en">A potential drug-drug interaction (PDDI) is an information content entity that specifies the possibility of a drug-drug interaction based on either reasonable extrapolation about drug-drug interaction mechanisms or a data item created by clinical studies, clinical observation or physiological experiment.</obo:IAO_0000115>
        <obo:IAO_0000117 xml:lang="en">Mathias Brochhausen</obo:IAO_0000117>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/DIDEO_00000002 -->

    <owl:Class rdf:about="&obo;DIDEO_00000002">
        <rdfs:label xml:lang="en">mechanistic assertion data item</rdfs:label>
        <rdfs:subClassOf rdf:resource="&obo;IAO_0000027"/>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/DIDEO_00000003 -->

    <owl:Class rdf:about="&obo;DIDEO_00000003">
        <rdfs:label xml:lang="en">observational data item about drug drug interaction</rdfs:label>
        <rdfs:subClassOf rdf:resource="&obo;IAO_0000027"/>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/DIDEO_00000004 -->

    <owl:Class rdf:about="&obo;DIDEO_00000004">
        <rdfs:label xml:lang="en">physiological observation from clinical study data item</rdfs:label>
        <rdfs:subClassOf rdf:resource="&obo;IAO_0000027"/>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/DIDEO_00000005 -->

    <owl:Class rdf:about="&obo;DIDEO_00000005">
        <rdfs:label xml:lang="en">data item from reasonable extrapolation</rdfs:label>
        <rdfs:subClassOf rdf:resource="&obo;IAO_0000027"/>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/DIDEO_00000011 -->

    <owl:Class rdf:about="&obo;DIDEO_00000011">
        <rdfs:label xml:lang="en">object drug information</rdfs:label>
        <rdfs:subClassOf rdf:resource="&obo;IAO_0000030"/>
        <rdfs:subClassOf>
            <owl:Class>
                <owl:intersectionOf rdf:parseType="Collection">
                    <owl:Restriction>
                        <owl:onProperty rdf:resource="&obo;IAO_0000136"/>
                        <owl:someValuesFrom rdf:resource="&obo;DIDEO_00000012"/>
                    </owl:Restriction>
                    <owl:Restriction>
                        <owl:onProperty rdf:resource="&obo;IAO_0000136"/>
                        <owl:someValuesFrom rdf:resource="&obo;DRON_00000005"/>
                    </owl:Restriction>
                </owl:intersectionOf>
            </owl:Class>
        </rdfs:subClassOf>
        <obo:IAO_0000115 xml:lang="en">An information content entity that makes a statement about a drug product being an object drug in a drug interaction.</obo:IAO_0000115>
        <obo:IAO_0000117 xml:lang="en">Mathias Brochhausen</obo:IAO_0000117>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/DIDEO_00000012 -->

    <owl:Class rdf:about="&obo;DIDEO_00000012">
        <rdfs:label xml:lang="en">object drug role</rdfs:label>
        <rdfs:subClassOf rdf:resource="&obo;BFO_0000023"/>
        <obo:IAO_0000117 xml:lang="en">Mathias Brochhausen</obo:IAO_0000117>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/DIDEO_00000013 -->

    <owl:Class rdf:about="&obo;DIDEO_00000013">
        <rdfs:label xml:lang="en">precipitant drug role</rdfs:label>
        <rdfs:subClassOf rdf:resource="&obo;BFO_0000023"/>
        <obo:IAO_0000117 xml:lang="en">Mathias Brochhausen</obo:IAO_0000117>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/DIDEO_00000014 -->

    <owl:Class rdf:about="&obo;DIDEO_00000014">
        <rdfs:label xml:lang="en">precipitant drug information</rdfs:label>
        <rdfs:subClassOf rdf:resource="&obo;IAO_0000030"/>
        <rdfs:subClassOf>
            <owl:Class>
                <owl:intersectionOf rdf:parseType="Collection">
                    <owl:Restriction>
                        <owl:onProperty rdf:resource="&obo;IAO_0000136"/>
                        <owl:someValuesFrom rdf:resource="&obo;DIDEO_00000013"/>
                    </owl:Restriction>
                    <owl:Restriction>
                        <owl:onProperty rdf:resource="&obo;IAO_0000136"/>
                        <owl:someValuesFrom rdf:resource="&obo;DRON_00000005"/>
                    </owl:Restriction>
                </owl:intersectionOf>
            </owl:Class>
        </rdfs:subClassOf>
        <obo:IAO_0000115 xml:lang="en">An information content entity that makes a statement about a drug product being an precipitant drug in a drug interaction.</obo:IAO_0000115>
        <obo:IAO_0000117 xml:lang="en">Mathias Brochhausen</obo:IAO_0000117>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/DIDEO_00000015 -->

    <owl:Class rdf:about="&obo;DIDEO_00000015">
        <rdfs:label xml:lang="en">metabolic potential drug drug interaction</rdfs:label>
        <owl:equivalentClass>
            <owl:Class>
                <owl:intersectionOf rdf:parseType="Collection">
                    <rdf:Description rdf:about="&obo;DIDEO_00000000"/>
                    <owl:Restriction>
                        <owl:onProperty rdf:resource="&obo;IAO_0000136"/>
                        <owl:someValuesFrom rdf:resource="http://purl.org/obo/owl/GO#GO_0017144"/>
                    </owl:Restriction>
                </owl:intersectionOf>
            </owl:Class>
        </owl:equivalentClass>
        <rdfs:subClassOf rdf:resource="&obo;DIDEO_00000000"/>
        <obo:IAO_0000115 xml:lang="en">A potential drug drug interaction that is about a drug metabolism.</obo:IAO_0000115>
        <obo:IAO_0000117 xml:lang="en">Mathias Brochhausen</obo:IAO_0000117>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/DIDEO_00000016 -->

    <owl:Class rdf:about="&obo;DIDEO_00000016">
        <rdfs:label xml:lang="en">narrow therapeutic index</rdfs:label>
        <rdfs:subClassOf rdf:resource="&obo;BFO_0000019"/>
        <rdfs:subClassOf>
            <owl:Restriction>
                <owl:onProperty rdf:resource="&obo;BFO_0000052"/>
                <owl:someValuesFrom rdf:resource="&obo;DRON_00000005"/>
            </owl:Restriction>
        </rdfs:subClassOf>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/DIDEO_00000017 -->

    <owl:Class rdf:about="&obo;DIDEO_00000017">
        <rdfs:label xml:lang="en">metabolism inhibition potential drug drug interaction</rdfs:label>
        <rdfs:subClassOf rdf:resource="&obo;DIDEO_00000015"/>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/DIDEO_00000018 -->

    <owl:Class rdf:about="&obo;DIDEO_00000018">
        <rdfs:label xml:lang="en">metabolism induction potential drug drug interaction</rdfs:label>
        <rdfs:subClassOf rdf:resource="&obo;DIDEO_00000015"/>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/DRON_00000005 -->

    <owl:Class rdf:about="&obo;DRON_00000005">
        <rdfs:label xml:lang="en">drug product</rdfs:label>
        <rdfs:subClassOf rdf:resource="&obo;BFO_0000040"/>
        <obo:IAO_0000412 rdf:datatype="&xsd;string">http://purl.obolibrary.org/obo/dron.owl</obo:IAO_0000412>
        <obo:IAO_0000117 xml:lang="en">William Hogan</obo:IAO_0000117>
        <dc:creator xml:lang="en">William Hogan</dc:creator>
        <obo:IAO_0000115 xml:lang="en">a material entity (1) containing at least one scattered molecular aggregate as part (the active ingredient) and (2) that is the bearer of a clinical drug role</obo:IAO_0000115>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/GO_0008150 -->

    <owl:Class rdf:about="&obo;GO_0008150">
        <rdfs:label rdf:datatype="&xsd;string">biological_process</rdfs:label>
        <rdfs:subClassOf rdf:resource="&obo;BFO_0000015"/>
        <obo:IAO_0000115 rdf:datatype="&xsd;string">Any process specifically pertinent to the functioning of integrated living units: cells, tissues, organs, and organisms. A process is a collection of molecular events with a defined beginning and end.</obo:IAO_0000115>
        <obo:IAO_0000111 rdf:datatype="&xsd;string">biological_process</obo:IAO_0000111>
        <obo:IAO_0000412 rdf:datatype="&xsd;string">http://purl.obolibrary.org/obo/obi.owl</obo:IAO_0000412>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/OBI_0000067 -->

    <owl:Class rdf:about="&obo;OBI_0000067">
        <rdfs:label xml:lang="en">evaluant role</rdfs:label>
        <rdfs:subClassOf rdf:resource="&obo;BFO_0000023"/>
        <obo:IAO_0000232 rdf:datatype="&xsd;string">Feb 10, 2009.  changes after discussion at OBI Consortium Workshop Feb 2-6, 2009.  accepted as core term.</obo:IAO_0000232>
        <obo:IAO_0000117 rdf:datatype="&xsd;string">GROUP:  Role Branch</obo:IAO_0000117>
        <obo:IAO_0000119 rdf:datatype="&xsd;string">OBI</obo:IAO_0000119>
        <obo:IAO_0000412 rdf:datatype="&xsd;string">http://purl.obolibrary.org/obo/obi.owl</obo:IAO_0000412>
        <obo:IAO_0000116 xml:lang="en">Role call - 17nov-08: JF and MC think an evaluant role is always specified input of a process. Even in the case where we have an assay taking blood as evaluant and outputting blood, the blood is not the specified output at the end of the assay (the concentration of glucose in the blood is)</obo:IAO_0000116>
        <obo:IAO_0000112 xml:lang="en">When a specimen of blood is assayed for glucose concentration, the blood has the evaluant role. When measuring the mass of a mouse, the evaluant is the mouse. When measuring the time of DNA replication, the evaluant is the DNA. When measuring the intensity of light on a surface, the evaluant is the light source.</obo:IAO_0000112>
        <obo:IAO_0000115 xml:lang="en">a role that inheres in a material entity that is realized in an assay in which data is generated about the bearer of the evaluant role</obo:IAO_0000115>
        <obo:IAO_0000111 xml:lang="en">evaluant role</obo:IAO_0000111>
        <obo:IAO_0000116 xml:lang="en">examples of features that could be described in an evaluant: quality.... e.g. &quot;contains 10 pg/ml IL2&quot;, or &quot;no glucose detected&quot;)</obo:IAO_0000116>
        <obo:IAO_0000114 rdf:resource="&obo;IAO_0000122"/>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/OBI_0000070 -->

    <owl:Class rdf:about="&obo;OBI_0000070">
        <rdfs:label xml:lang="en">assay</rdfs:label>
        <rdfs:subClassOf rdf:resource="&obo;OBI_0000011"/>
        <obo:IAO_0000112 rdf:datatype="&xsd;string">Assay the wavelength of light emitted by excited Neon atoms. Count of geese flying over a house.</obo:IAO_0000112>
        <obo:OBI_9991118 rdf:datatype="&xsd;string">any method</obo:OBI_9991118>
        <obo:IAO_0000412 rdf:datatype="&xsd;string">http://purl.obolibrary.org/obo/obi.owl</obo:IAO_0000412>
        <obo:OBI_0001847 rdf:datatype="&xsd;string">study assay</obo:OBI_0001847>
        <obo:IAO_0000116>12/3/12: BP: the reference to the &apos;physical examination&apos; is included to point out that a prediction is not an assay, as that does not require physical examiniation. </obo:IAO_0000116>
        <obo:IAO_0000115 xml:lang="en">A planned process with the objective to produce information about the material entity that is the evaluant, by physically examining it or its proxies.</obo:IAO_0000115>
        <obo:IAO_0000119 xml:lang="en">OBI branch derived</obo:IAO_0000119>
        <obo:IAO_0000117 xml:lang="en">PlanAndPlannedProcess Branch</obo:IAO_0000117>
        <obo:IAO_0000111 xml:lang="en">assay</obo:IAO_0000111>
        <obo:IAO_0000118 xml:lang="en">measuring</obo:IAO_0000118>
        <obo:IAO_0000118 xml:lang="en">scientific observation</obo:IAO_0000118>
        <obo:IAO_0000114 rdf:resource="&obo;IAO_0000122"/>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/OBI_0000427 -->

    <owl:Class rdf:about="&obo;OBI_0000427">
        <rdfs:label xml:lang="en">enzyme</rdfs:label>
        <rdfs:subClassOf rdf:resource="&obo;BFO_0000040"/>
        <obo:IAO_0000119 rdf:datatype="&xsd;string">GROUP:OBI</obo:IAO_0000119>
        <obo:IAO_0000116 rdf:datatype="&xsd;string">MC: known issue: enzyme doesn&apos;t classify under material entity for now as it isn&apos;t stated that anything
that has_part some material entity is a material entity. If we add as equivalent classes to material entity has_part some material entity and part_of some material entity  (each one in his own necessary and sufficient block) Pellet in P3 doesn&apos;t classify any more.</obo:IAO_0000116>
        <obo:IAO_0000412 rdf:datatype="&xsd;string">http://purl.obolibrary.org/obo/obi.owl</obo:IAO_0000412>
        <obo:IAO_0000117 rdf:datatype="&xsd;string">person: Melanie Courtot</obo:IAO_0000117>
        <obo:IAO_0000115 xml:lang="en">(protein or rna) or has_part (protein or rna) and
has_function some GO:0003824 (catalytic activity)</obo:IAO_0000115>
        <obo:IAO_0000111 xml:lang="en">enzyme</obo:IAO_0000111>
        <obo:IAO_0000114 rdf:resource="&obo;IAO_0000125"/>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/OBI_0500000 -->

    <owl:Class rdf:about="&obo;OBI_0500000">
        <rdfs:label xml:lang="en">study design</rdfs:label>
        <rdfs:subClassOf rdf:resource="&obo;IAO_0000104"/>
        <obo:IAO_0000115 rdf:datatype="&xsd;string">A plan specification comprised of protocols (which may specify how and what kinds of data will be gathered) that are executed as part of an investigation and is realized during a study design execution.</obo:IAO_0000115>
        <obo:IAO_0000116 rdf:datatype="&xsd;string">Editor note: there is at least an implicit restriction on the kind of data transformations that can be done based on the measured data available.</obo:IAO_0000116>
        <obo:IAO_0000117 rdf:datatype="&xsd;string">PERSON: Chris Stoeckert</obo:IAO_0000117>
        <obo:IAO_0000412 rdf:datatype="&xsd;string">http://purl.obolibrary.org/obo/obi.owl</obo:IAO_0000412>
        <obo:IAO_0000112 xml:lang="en">a matched pairs study design describes criteria by which subjects are identified as pairs which then undergo the same protocols, and the data generated is analyzed by comparing the differences between the paired subjects, which constitute the results of the executed study design.</obo:IAO_0000112>
        <obo:IAO_0000118 xml:lang="en">experimental design</obo:IAO_0000118>
        <obo:IAO_0000232 xml:lang="en">rediscussed at length (MC/JF/BP). 12/9/08). The definition was clarified to differentiate it from protocol.</obo:IAO_0000232>
        <obo:IAO_0000111 xml:lang="en">study design</obo:IAO_0000111>
        <obo:IAO_0000114 rdf:resource="&obo;IAO_0000122"/>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/OBI_0500001 -->

    <owl:Class rdf:about="&obo;OBI_0500001">
        <rdfs:label xml:lang="en">clinical study design</rdfs:label>
        <rdfs:subClassOf rdf:resource="&obo;OBI_0500000"/>
        <obo:IAO_0000412 rdf:datatype="&xsd;string">http://purl.obolibrary.org/obo/obi.owl</obo:IAO_0000412>
        <obo:IAO_0000119 xml:lang="en">Clinical Research Glossary Version 4.0 CDICS glossary group</obo:IAO_0000119>
        <obo:IAO_0000112 xml:lang="en">PMID: 17655677.J Cardiovasc Electrophysiol. 2007 Aug;18(9):965-71.Biventricular versus right ventricular pacing in patients with AV block (BLOCK HF): clinical study design and rationale.</obo:IAO_0000112>
        <obo:IAO_0000115 xml:lang="en">Plan for the precise procedure to be followed in a clinical trial, including planned and actual timing of events, choice of control group, method of allocating treatments, blinding methods; assigns a subject to pass through one or more epochs in the course of a trial. Specific design elements, e.g., crossover, parallel; dose-escalation [Modified from Pocock, Clinical Trials: A Practical Approach]</obo:IAO_0000115>
        <obo:IAO_0000117 xml:lang="en">PlanAndPlannedProcess Branch</obo:IAO_0000117>
        <obo:IAO_0000116 xml:lang="en">The definition needs to be extended to other things than simply patients</obo:IAO_0000116>
        <obo:IAO_0000111 xml:lang="en">clinical study design</obo:IAO_0000111>
        <obo:IAO_0000114 rdf:resource="&obo;IAO_0000125"/>
    </owl:Class>
    


    <!-- http://purl.org/obo/owl/GO#GO_0009987 -->

    <owl:Class rdf:about="http://purl.org/obo/owl/GO#GO_0009987">
        <rdfs:label xml:lang="en">cellular process</rdfs:label>
        <rdfs:subClassOf rdf:resource="&obo;GO_0008150"/>
        <obo:IAO_0000412 rdf:datatype="&xsd;string">http://purl.org/obo/owl/go_xp_all</obo:IAO_0000412>
        <oboInOwl:hasAlternativeId>GO:0050875</oboInOwl:hasAlternativeId>
        <oboInOwl:hasAlternativeId>GO:0008151</oboInOwl:hasAlternativeId>
        <oboInOwl:hasOBONamespace>biological_process</oboInOwl:hasOBONamespace>
        <oboInOwl:inSubset rdf:resource="http://purl.org/obo/owl/obo#goslim_goa"/>
        <oboInOwl:inSubset rdf:resource="http://purl.org/obo/owl/obo#goslim_pir"/>
        <oboInOwl:inSubset rdf:resource="http://purl.org/obo/owl/obo#goslim_plant"/>
        <oboInOwl:inSubset rdf:resource="http://purl.org/obo/owl/obo#gosubset_prok"/>
        <oboInOwl:hasDefinition>
            <rdf:Description/>
        </oboInOwl:hasDefinition>
        <oboInOwl:hasExactSynonym>
            <rdf:Description/>
        </oboInOwl:hasExactSynonym>
        <oboInOwl:hasNarrowSynonym>
            <rdf:Description/>
        </oboInOwl:hasNarrowSynonym>
        <oboInOwl:hasExactSynonym>
            <rdf:Description/>
        </oboInOwl:hasExactSynonym>
    </owl:Class>
    


    <!-- http://purl.org/obo/owl/GO#GO_0017144 -->

    <owl:Class rdf:about="http://purl.org/obo/owl/GO#GO_0017144">
        <rdfs:label xml:lang="en">drug metabolic process</rdfs:label>
        <rdfs:subClassOf rdf:resource="http://purl.org/obo/owl/GO#GO_0009987"/>
        <obo:IAO_0000412 rdf:datatype="&xsd;string">http://purl.org/obo/owl/go_xp_all</obo:IAO_0000412>
        <oboInOwl:hasOBONamespace>biological_process</oboInOwl:hasOBONamespace>
        <oboInOwl:inSubset rdf:resource="http://purl.org/obo/owl/obo#goslim_pir"/>
        <oboInOwl:inSubset rdf:resource="http://purl.org/obo/owl/obo#gosubset_prok"/>
        <oboInOwl:hasDbXref>
            <rdf:Description/>
        </oboInOwl:hasDbXref>
        <oboInOwl:hasDbXref>
            <rdf:Description/>
        </oboInOwl:hasDbXref>
        <oboInOwl:hasDbXref>
            <rdf:Description/>
        </oboInOwl:hasDbXref>
        <oboInOwl:hasExactSynonym>
            <rdf:Description/>
        </oboInOwl:hasExactSynonym>
        <oboInOwl:hasDbXref>
            <rdf:Description/>
        </oboInOwl:hasDbXref>
        <oboInOwl:hasDefinition>
            <rdf:Description/>
        </oboInOwl:hasDefinition>
        <oboInOwl:hasDbXref>
            <rdf:Description/>
        </oboInOwl:hasDbXref>
    </owl:Class>
    


    <!-- 
    ///////////////////////////////////////////////////////////////////////////////////////
    //
    // Individuals
    //
    ///////////////////////////////////////////////////////////////////////////////////////
     -->

    


    <!-- http://127.0.0.1:3333/1 -->

    <owl:NamedIndividual rdf:about="http://127.0.0.1:3333/1">
        <rdf:type rdf:resource="&obo;DIDEO_00000000"/>
        <rdfs:comment>diltiazem_increases_auc_triazolam</rdfs:comment>
        <rdfs:comment>boycer</rdfs:comment>
        <rdfs:comment>diltiazem increases the AUC of triazolam </rdfs:comment>
        <rdfs:comment>None</rdfs:comment>
        <rdfs:comment>2.835</rdfs:comment>
        <obo:IAO_0000136>DILTIAZEM</obo:IAO_0000136>
        <rdfs:comment>http://www.ncbi.nlm.nih.gov/pubmed/8612379</rdfs:comment>
        <rdfs:comment>DIKB</rdfs:comment>
        <rdfs:comment>DDIObservation</rdfs:comment>
        <rdfs:comment>http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/diltiazem_increases_auc_triazolam.html</rdfs:comment>
        <rdfs:comment>07/02/2007 17:38:07</rdfs:comment>
        <rdfs:comment>http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/increases_auc</rdfs:comment>
        <rdfs:comment>|Route of administration: oral|study duration: 1 day pretreatment with diltiazem given 3x/day @ 60mg PO. On day two .25mg triazolam was given PO|population: 10 subjects, male: 3 female: 7|ages: 18-31|AUC_i/AUC 0-time of measurement (17hrs): 36.0/12.7 = 2.835|AUC_i/AUC 0 -inf: 47/13.9 = 3.381|</rdfs:comment>
        <obo:IAO_0000136>TRIAZOLAM</obo:IAO_0000136>
        <rdfs:comment>http://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/39</rdfs:comment>
        <rdfs:comment>http://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/30</rdfs:comment>
        <rdfs:comment>http://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/DDIObservations1</rdfs:comment>
        <obo:IAO_0000136 rdf:resource="&obo;CHEBI_101278"/>
        <obo:IAO_0000136 rdf:resource="&obo;CHEBI_9674"/>
    </owl:NamedIndividual>
    


    <!-- http://127.0.0.1:3333/11490 -->

    <owl:NamedIndividual rdf:about="http://127.0.0.1:3333/11490">
        <rdf:type rdf:resource="&obo;DIDEO_00000000"/>
        <obo:IAO_0000136>Simvastatin</obo:IAO_0000136>
        <rdfs:comment>None</rdfs:comment>
        <rdfs:comment>Increased risk of myopathy/rhabdomyolysis|</rdfs:comment>
        <rdfs:comment>Drugbank</rdfs:comment>
        <obo:IAO_0000136>Itraconazole</obo:IAO_0000136>
        <obo:IAO_0000136 rdf:resource="&obo;CHEBI_6076"/>
        <obo:IAO_0000136 rdf:resource="&obo;CHEBI_9150"/>
    </owl:NamedIndividual>
    


    <!-- http://127.0.0.1:3333/16268 -->

    <owl:NamedIndividual rdf:about="http://127.0.0.1:3333/16268">
        <rdf:type rdf:resource="&obo;DIDEO_00000000"/>
        <obo:IAO_0000136>Diltiazem</obo:IAO_0000136>
        <rdfs:comment>Diltiazem may increase the serum concentration of simvastatin. Simvastatin may increase the serum concentration of diltiazem. Monitor for changes in the therapeutic and adverse effects of both agents if concomitant therapy is initiated, discontinued or if doses are changed.|</rdfs:comment>
        <obo:IAO_0000136>Simvastatin</obo:IAO_0000136>
        <rdfs:comment>None</rdfs:comment>
        <rdfs:comment>Drugbank</rdfs:comment>
        <obo:IAO_0000136 rdf:resource="&obo;CHEBI_101278"/>
        <obo:IAO_0000136 rdf:resource="&obo;CHEBI_9150"/>
    </owl:NamedIndividual>
    


    <!-- http://127.0.0.1:3333/17416 -->

    <owl:NamedIndividual rdf:about="http://127.0.0.1:3333/17416">
        <rdf:type rdf:resource="&obo;DIDEO_00000000"/>
        <rdfs:comment>Drugbank</rdfs:comment>
        <obo:IAO_0000136>Ketoconazole</obo:IAO_0000136>
        <rdfs:comment>None</rdfs:comment>
        <obo:IAO_0000136>Atorvastatin</obo:IAO_0000136>
        <rdfs:comment>Increased risk of myopathy/rhabdomyolysis|</rdfs:comment>
        <obo:IAO_0000136 rdf:resource="&obo;CHEBI_39548"/>
        <obo:IAO_0000136 rdf:resource="&obo;CHEBI_48339"/>
    </owl:NamedIndividual>
    


    <!-- http://127.0.0.1:3333/190 -->

    <owl:NamedIndividual rdf:about="http://127.0.0.1:3333/190">
        <rdf:type rdf:resource="&obo;DIDEO_00000000"/>
        <rdfs:comment>DDIPrediction</rdfs:comment>
        <obo:IAO_0000136>simvastatin</obo:IAO_0000136>
        <rdfs:comment>None</rdfs:comment>
        <rdfs:comment>DIKB</rdfs:comment>
        <rdfs:comment>http://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/DDIPredictions/376</rdfs:comment>
        <rdfs:comment>itraconazole is predicted to reduce the clearance of simvastatin by inhibition of CYP3A4</rdfs:comment>
        <obo:IAO_0000136>itraconazole</obo:IAO_0000136>
        <rdfs:comment>http://purl.obolibrary.org/obo/PR_000006130</rdfs:comment>
        <obo:IAO_0000136 rdf:resource="&obo;CHEBI_6076"/>
        <obo:IAO_0000136 rdf:resource="&obo;CHEBI_9150"/>
    </owl:NamedIndividual>
    


    <!-- http://127.0.0.1:3333/19816 -->

    <owl:NamedIndividual rdf:about="http://127.0.0.1:3333/19816">
        <rdf:type rdf:resource="&obo;DIDEO_00000000"/>
        <rdfs:comment>None</rdfs:comment>
        <obo:IAO_0000136>Fluvastatin</obo:IAO_0000136>
        <rdfs:comment>Drugbank</rdfs:comment>
        <rdfs:comment>Fluconazole may increase the serum concentration of fluvastatin by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of fluvastatin if fluconazole is initiated, discontinued or dose changed.|</rdfs:comment>
        <obo:IAO_0000136>Fluconazole</obo:IAO_0000136>
        <obo:IAO_0000136 rdf:resource="&obo;CHEBI_38561"/>
        <obo:IAO_0000136 rdf:resource="&obo;CHEBI_46081"/>
    </owl:NamedIndividual>
    


    <!-- http://127.0.0.1:3333/210 -->

    <owl:NamedIndividual rdf:about="http://127.0.0.1:3333/210">
        <rdf:type rdf:resource="&obo;DIDEO_00000000"/>
        <rdfs:comment>None</rdfs:comment>
        <obo:IAO_0000136>diltiazem</obo:IAO_0000136>
        <rdfs:comment>diltiazem is predicted to reduce the clearance of simvastatin by inhibition of CYP3A4</rdfs:comment>
        <rdfs:comment>http://purl.obolibrary.org/obo/PR_000006130</rdfs:comment>
        <rdfs:comment>http://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/DDIPredictions/395</rdfs:comment>
        <obo:IAO_0000136>simvastatin</obo:IAO_0000136>
        <rdfs:comment>DDIPrediction</rdfs:comment>
        <rdfs:comment>DIKB</rdfs:comment>
        <obo:IAO_0000136 rdf:resource="&obo;CHEBI_101278"/>
        <obo:IAO_0000136 rdf:resource="&obo;CHEBI_9150"/>
    </owl:NamedIndividual>
    


    <!-- http://127.0.0.1:3333/219 -->

    <owl:NamedIndividual rdf:about="http://127.0.0.1:3333/219">
        <rdf:type rdf:resource="&obo;DIDEO_00000000"/>
        <obo:IAO_0000136>triazolam</obo:IAO_0000136>
        <rdfs:comment>None</rdfs:comment>
        <rdfs:comment>http://purl.obolibrary.org/obo/PR_000006130</rdfs:comment>
        <rdfs:comment>DDIPrediction</rdfs:comment>
        <rdfs:comment>http://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/DDIPredictions/707</rdfs:comment>
        <rdfs:comment>diltiazem is predicted to reduce the clearance of triazolam by inhibition of CYP3A4</rdfs:comment>
        <obo:IAO_0000136>diltiazem</obo:IAO_0000136>
        <rdfs:comment>DIKB</rdfs:comment>
        <obo:IAO_0000136 rdf:resource="&obo;CHEBI_101278"/>
        <obo:IAO_0000136 rdf:resource="&obo;CHEBI_9674"/>
    </owl:NamedIndividual>
    


    <!-- http://127.0.0.1:3333/23279 -->

    <owl:NamedIndividual rdf:about="http://127.0.0.1:3333/23279">
        <rdf:type rdf:resource="&obo;DIDEO_00000000"/>
        <obo:IAO_0000136>Ketoconazole</obo:IAO_0000136>
        <rdfs:comment>Drugbank</rdfs:comment>
        <obo:IAO_0000136>Lovastatin</obo:IAO_0000136>
        <rdfs:comment>Increased risk of myopathy/rhabdomyolysis|</rdfs:comment>
        <rdfs:comment>None</rdfs:comment>
        <obo:IAO_0000136 rdf:resource="&obo;CHEBI_40303"/>
        <obo:IAO_0000136 rdf:resource="&obo;CHEBI_48339"/>
    </owl:NamedIndividual>
    


    <!-- http://127.0.0.1:3333/23427 -->

    <owl:NamedIndividual rdf:about="http://127.0.0.1:3333/23427">
        <rdf:type rdf:resource="&obo;DIDEO_00000000"/>
        <obo:IAO_0000136>Diltiazem</obo:IAO_0000136>
        <obo:IAO_0000136>Triazolam</obo:IAO_0000136>
        <rdfs:comment>None</rdfs:comment>
        <rdfs:comment>The calcium channel blocker, diltiazem, may increase the effect and toxicity of the benzodiazepine, triazolam.|</rdfs:comment>
        <rdfs:comment>Drugbank</rdfs:comment>
        <obo:IAO_0000136 rdf:resource="&obo;CHEBI_101278"/>
        <obo:IAO_0000136 rdf:resource="&obo;CHEBI_9674"/>
    </owl:NamedIndividual>
    


    <!-- http://127.0.0.1:3333/26 -->

    <owl:NamedIndividual rdf:about="http://127.0.0.1:3333/26">
        <rdf:type rdf:resource="&obo;DIDEO_00000000"/>
        <rdfs:comment>None</rdfs:comment>
        <rdfs:comment>DDIObservation</rdfs:comment>
        <rdfs:comment>http://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/663</rdfs:comment>
        <rdfs:comment>fluconazole_increases_auc_fluvastatin</rdfs:comment>
        <rdfs:comment>DIKB</rdfs:comment>
        <obo:IAO_0000136>FLUCONAZOLE</obo:IAO_0000136>
        <rdfs:comment>http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/increases_auc</rdfs:comment>
        <obo:IAO_0000136>FLUVASTATIN</obo:IAO_0000136>
        <rdfs:comment>|Route of administration: oral|study duration: 4 days pretreatment with oral fluconazole 400mg day 1 and 200mg days 2-4; on day 4 a single oral dose of 40mg fluvastatin|population: 12|male: 5|female: 7|ages: 19-26|AUC_i/AUC 0 to infinity: 955 / 520 = 1.837</rdfs:comment>
        <rdfs:comment>1.837</rdfs:comment>
        <rdfs:comment>http://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/DDIObservations36</rdfs:comment>
        <rdfs:comment>http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/fluconazole_increases_auc_fluvastatin.html</rdfs:comment>
        <rdfs:comment>fluconazole increases the AUC of fluvastatin </rdfs:comment>
        <rdfs:comment>10/29/2007 11:59:09</rdfs:comment>
        <rdfs:comment>http://www.ncbi.nlm.nih.gov/pubmed/10952477</rdfs:comment>
        <rdfs:comment>boycer</rdfs:comment>
        <rdfs:comment>http://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/557</rdfs:comment>
        <obo:IAO_0000136 rdf:resource="&obo;CHEBI_38561"/>
        <obo:IAO_0000136 rdf:resource="&obo;CHEBI_46081"/>
    </owl:NamedIndividual>
    


    <!-- http://127.0.0.1:3333/26569 -->

    <owl:NamedIndividual rdf:about="http://127.0.0.1:3333/26569">
        <rdf:type rdf:resource="&obo;DIDEO_00000000"/>
        <rdfs:comment>None</rdfs:comment>
        <rdfs:comment>DILTIAZEM/SIMVASTATIN [VA Drug Interaction]</rdfs:comment>
        <obo:IAO_0000136>Diltiazem</obo:IAO_0000136>
        <rdfs:comment>Significant</rdfs:comment>
        <rdfs:comment>NDF-RT</rdfs:comment>
        <obo:IAO_0000136>SIMVASTATIN</obo:IAO_0000136>
        <rdfs:comment>http://purl.bioontology.org/ontology/NDFRT/N0000033997</rdfs:comment>
        <obo:IAO_0000136 rdf:resource="&obo;CHEBI_101278"/>
        <obo:IAO_0000136 rdf:resource="&obo;CHEBI_9150"/>
    </owl:NamedIndividual>
    


    <!-- http://127.0.0.1:3333/27011 -->

    <owl:NamedIndividual rdf:about="http://127.0.0.1:3333/27011">
        <rdf:type rdf:resource="&obo;DIDEO_00000000"/>
        <rdfs:comment>None</rdfs:comment>
        <obo:IAO_0000136>Diltiazem</obo:IAO_0000136>
        <rdfs:comment>DILTIAZEM/TRIAZOLAM [VA Drug Interaction]</rdfs:comment>
        <obo:IAO_0000136>TRIAZOLAM</obo:IAO_0000136>
        <rdfs:comment>Significant</rdfs:comment>
        <rdfs:comment>NDF-RT</rdfs:comment>
        <rdfs:comment>http://purl.bioontology.org/ontology/NDFRT/N0000034907</rdfs:comment>
        <obo:IAO_0000136 rdf:resource="&obo;CHEBI_101278"/>
        <obo:IAO_0000136 rdf:resource="&obo;CHEBI_9674"/>
    </owl:NamedIndividual>
    


    <!-- http://127.0.0.1:3333/362 -->

    <owl:NamedIndividual rdf:about="http://127.0.0.1:3333/362">
        <rdf:type rdf:resource="&obo;DIDEO_00000000"/>
        <rdfs:comment>http://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/DDIPredictions/369</rdfs:comment>
        <rdfs:comment>ketoconazole is predicted to reduce the clearance of atorvastatin by inhibition of CYP3A4</rdfs:comment>
        <rdfs:comment>DIKB</rdfs:comment>
        <rdfs:comment>None</rdfs:comment>
        <obo:IAO_0000136>ketoconazole</obo:IAO_0000136>
        <rdfs:comment>DDIPrediction</rdfs:comment>
        <rdfs:comment>http://purl.obolibrary.org/obo/PR_000006130</rdfs:comment>
        <obo:IAO_0000136>atorvastatin</obo:IAO_0000136>
        <obo:IAO_0000136 rdf:resource="&obo;CHEBI_39548"/>
        <obo:IAO_0000136 rdf:resource="&obo;CHEBI_48339"/>
    </owl:NamedIndividual>
    


    <!-- http://127.0.0.1:3333/364 -->

    <owl:NamedIndividual rdf:about="http://127.0.0.1:3333/364">
        <rdf:type rdf:resource="&obo;DIDEO_00000000"/>
        <rdfs:comment>None</rdfs:comment>
        <rdfs:comment>http://purl.obolibrary.org/obo/PR_000006130</rdfs:comment>
        <rdfs:comment>http://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/DDIPredictions/371</rdfs:comment>
        <obo:IAO_0000136>lovastatin</obo:IAO_0000136>
        <rdfs:comment>DDIPrediction</rdfs:comment>
        <rdfs:comment>ketoconazole is predicted to reduce the clearance of lovastatin by inhibition of CYP3A4</rdfs:comment>
        <rdfs:comment>DIKB</rdfs:comment>
        <obo:IAO_0000136>ketoconazole</obo:IAO_0000136>
        <obo:IAO_0000136 rdf:resource="&obo;CHEBI_40303"/>
        <obo:IAO_0000136 rdf:resource="&obo;CHEBI_48339"/>
    </owl:NamedIndividual>
    


    <!-- http://127.0.0.1:3333/37 -->

    <owl:NamedIndividual rdf:about="http://127.0.0.1:3333/37">
        <rdf:type rdf:resource="&obo;DIDEO_00000000"/>
        <rdfs:comment>4.817</rdfs:comment>
        <rdfs:comment>http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/increases_auc</rdfs:comment>
        <rdfs:comment>05/29/2007 10:27:50</rdfs:comment>
        <rdfs:comment>http://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/689</rdfs:comment>
        <rdfs:comment>http://www.ncbi.nlm.nih.gov/pubmed/10741630</rdfs:comment>
        <rdfs:comment>|Route of administration: oral|polymorphic enzyme: NO|study duration: 14 days diltiazem pretreatment|population: 5 male, 5 women|ages:19-35|(mean AUC_i)/(mean AUC) = 55.4/11.5|description: |A fixed-order study was conducted in 10 healthy volunteers with a 2-week washout period between the phases. In one arm of the study, a single 20-mg dose of simvastatin was administered orally; the second arm entailed administration of a single 20-mg dose of simvastatin orally after 2 weeks of treatment with 120 mg diltiazem twice a day. RESULTS: Diltiazem significantly increased the mean peak serum concentration of simvastatin by 3.6-fold (P &lt; .05) and simvastatin acid by 3.7-fold (P &lt; .05). Diltiazem also significantly increased the area under the serum concentration-time curve of simvastatin 5-fold (P &lt; .05) and the elimination half-life 2.3-fold (P &lt; .05).</rdfs:comment>
        <rdfs:comment>DDIObservation</rdfs:comment>
        <rdfs:comment>diltiazem_increases_auc_simvastatin</rdfs:comment>
        <rdfs:comment>http://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/DDIObservations47</rdfs:comment>
        <obo:IAO_0000136>DILTIAZEM</obo:IAO_0000136>
        <rdfs:comment>DIKB</rdfs:comment>
        <rdfs:comment>http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/diltiazem_increases_auc_simvastatin.html</rdfs:comment>
        <rdfs:comment>http://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/830</rdfs:comment>
        <rdfs:comment>boycer</rdfs:comment>
        <rdfs:comment>None</rdfs:comment>
        <obo:IAO_0000136>SIMVASTATIN</obo:IAO_0000136>
        <rdfs:comment>diltiazem increases the AUC of simvastatin </rdfs:comment>
        <obo:IAO_0000136 rdf:resource="&obo;CHEBI_101278"/>
        <obo:IAO_0000136 rdf:resource="&obo;CHEBI_9150"/>
    </owl:NamedIndividual>
    


    <!-- http://127.0.0.1:3333/43751 -->

    <owl:NamedIndividual rdf:about="http://127.0.0.1:3333/43751">
        <rdf:type rdf:resource="&obo;DIDEO_00000000"/>
        <rdfs:comment>http://rest.kegg.jp/ddi/D00434</rdfs:comment>
        <rdfs:comment>Kegg</rdfs:comment>
        <obo:IAO_0000136>Simvastatin</obo:IAO_0000136>
        <obo:IAO_0000136>Itraconazole</obo:IAO_0000136>
        <rdfs:comment>True</rdfs:comment>
        <rdfs:comment>None</rdfs:comment>
        <obo:IAO_0000136 rdf:resource="&obo;CHEBI_6076"/>
        <obo:IAO_0000136 rdf:resource="&obo;CHEBI_9150"/>
    </owl:NamedIndividual>
    


    <!-- http://127.0.0.1:3333/43774 -->

    <owl:NamedIndividual rdf:about="http://127.0.0.1:3333/43774">
        <rdf:type rdf:resource="&obo;DIDEO_00000000"/>
        <rdfs:comment>True</rdfs:comment>
        <rdfs:comment>Kegg</rdfs:comment>
        <rdfs:comment>http://rest.kegg.jp/ddi/D00434</rdfs:comment>
        <obo:IAO_0000136>Simvastatin</obo:IAO_0000136>
        <obo:IAO_0000136>Amiodarone</obo:IAO_0000136>
        <rdfs:comment>None</rdfs:comment>
        <obo:IAO_0000136 rdf:resource="&obo;CHEBI_2663"/>
        <obo:IAO_0000136 rdf:resource="&obo;CHEBI_9150"/>
    </owl:NamedIndividual>
    


    <!-- http://127.0.0.1:3333/444 -->

    <owl:NamedIndividual rdf:about="http://127.0.0.1:3333/444">
        <rdf:type rdf:resource="&obo;DIDEO_00000000"/>
        <rdfs:comment>None</rdfs:comment>
        <obo:IAO_0000136>fluconazole</obo:IAO_0000136>
        <rdfs:comment>DDIPrediction</rdfs:comment>
        <rdfs:comment>http://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/DDIPredictions/421</rdfs:comment>
        <obo:IAO_0000136>rosuvastatin</obo:IAO_0000136>
        <rdfs:comment>http://purl.obolibrary.org/obo/PR_000006120</rdfs:comment>
        <rdfs:comment>DIKB</rdfs:comment>
        <rdfs:comment>fluconazole is predicted to reduce the clearance of rosuvastatin by inhibition of CYP2C9</rdfs:comment>
        <obo:IAO_0000136 rdf:resource="&obo;CHEBI_38545"/>
        <obo:IAO_0000136 rdf:resource="&obo;CHEBI_46081"/>
    </owl:NamedIndividual>
    


    <!-- http://127.0.0.1:3333/473 -->

    <owl:NamedIndividual rdf:about="http://127.0.0.1:3333/473">
        <rdf:type rdf:resource="&obo;DIDEO_00000000"/>
        <rdfs:comment>http://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/DDIPredictions/384</rdfs:comment>
        <obo:IAO_0000136>fluconazole</obo:IAO_0000136>
        <rdfs:comment>None</rdfs:comment>
        <rdfs:comment>fluconazole is predicted to reduce the clearance of fluvastatin by inhibition of CYP3A4</rdfs:comment>
        <obo:IAO_0000136>fluvastatin</obo:IAO_0000136>
        <rdfs:comment>DIKB</rdfs:comment>
        <rdfs:comment>http://purl.obolibrary.org/obo/PR_000006130</rdfs:comment>
        <rdfs:comment>DDIPrediction</rdfs:comment>
        <obo:IAO_0000136 rdf:resource="&obo;CHEBI_38561"/>
        <obo:IAO_0000136 rdf:resource="&obo;CHEBI_46081"/>
    </owl:NamedIndividual>
    


    <!-- http://127.0.0.1:3333/476 -->

    <owl:NamedIndividual rdf:about="http://127.0.0.1:3333/476">
        <rdf:type rdf:resource="&obo;DIDEO_00000000"/>
        <rdfs:comment>http://purl.obolibrary.org/obo/PR_000006120</rdfs:comment>
        <rdfs:comment>http://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/DDIPredictions/387</rdfs:comment>
        <rdfs:comment>None</rdfs:comment>
        <rdfs:comment>DIKB</rdfs:comment>
        <obo:IAO_0000136>fluconazole</obo:IAO_0000136>
        <rdfs:comment>DDIPrediction</rdfs:comment>
        <obo:IAO_0000136>fluvastatin</obo:IAO_0000136>
        <rdfs:comment>fluconazole is predicted to reduce the clearance of fluvastatin by inhibition of CYP2C9</rdfs:comment>
        <obo:IAO_0000136 rdf:resource="&obo;CHEBI_38561"/>
        <obo:IAO_0000136 rdf:resource="&obo;CHEBI_46081"/>
    </owl:NamedIndividual>
    


    <!-- http://127.0.0.1:3333/5983 -->

    <owl:NamedIndividual rdf:about="http://127.0.0.1:3333/5983">
        <rdf:type rdf:resource="&obo;DIDEO_00000000"/>
        <rdfs:comment>Drugbank</rdfs:comment>
        <obo:IAO_0000136>Amiodarone</obo:IAO_0000136>
        <rdfs:comment>Increased risk of rhabdomyolysis|</rdfs:comment>
        <obo:IAO_0000136>Simvastatin</obo:IAO_0000136>
        <rdfs:comment>None</rdfs:comment>
        <obo:IAO_0000136 rdf:resource="&obo;CHEBI_2663"/>
        <obo:IAO_0000136 rdf:resource="&obo;CHEBI_9150"/>
    </owl:NamedIndividual>
    


    <!-- http://127.0.0.1:3333/623 -->

    <owl:NamedIndividual rdf:about="http://127.0.0.1:3333/623">
        <rdf:type rdf:resource="&obo;DIDEO_00000000"/>
        <obo:IAO_0000136>amiodarone</obo:IAO_0000136>
        <rdfs:comment>DIKB</rdfs:comment>
        <rdfs:comment>None</rdfs:comment>
        <rdfs:comment>amiodarone is predicted to reduce the clearance of simvastatin by inhibition of CYP3A4</rdfs:comment>
        <rdfs:comment>DDIPrediction</rdfs:comment>
        <rdfs:comment>http://purl.obolibrary.org/obo/PR_000006130</rdfs:comment>
        <obo:IAO_0000136>simvastatin</obo:IAO_0000136>
        <rdfs:comment>http://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/DDIPredictions/414</rdfs:comment>
        <obo:IAO_0000136 rdf:resource="&obo;CHEBI_2663"/>
        <obo:IAO_0000136 rdf:resource="&obo;CHEBI_9150"/>
    </owl:NamedIndividual>
    


    <!-- http://127.0.0.1:3333/64583 -->

    <owl:NamedIndividual rdf:about="http://127.0.0.1:3333/64583">
        <rdf:type rdf:resource="&obo;DIDEO_00000000"/>
        <obo:IAO_0000136>Fluconazole</obo:IAO_0000136>
        <obo:IAO_0000136>Rosuvastatin</obo:IAO_0000136>
        <rdfs:comment>None</rdfs:comment>
        <rdfs:comment>True</rdfs:comment>
        <rdfs:comment>Kegg</rdfs:comment>
        <rdfs:comment>http://rest.kegg.jp/ddi/D01915</rdfs:comment>
        <rdfs:comment>unclassified</rdfs:comment>
        <obo:IAO_0000136 rdf:resource="&obo;CHEBI_38545"/>
        <obo:IAO_0000136 rdf:resource="&obo;CHEBI_46081"/>
    </owl:NamedIndividual>
    


    <!-- http://127.0.0.1:3333/76338 -->

    <owl:NamedIndividual rdf:about="http://127.0.0.1:3333/76338">
        <rdf:type rdf:resource="&obo;DIDEO_00000000"/>
        <obo:IAO_0000136>Fluvastatin</obo:IAO_0000136>
        <rdfs:comment>http://rest.kegg.jp/ddi/D07983</rdfs:comment>
        <obo:IAO_0000136>Fluconazole</obo:IAO_0000136>
        <rdfs:comment>None</rdfs:comment>
        <rdfs:comment>Kegg</rdfs:comment>
        <rdfs:comment>True</rdfs:comment>
        <obo:IAO_0000136 rdf:resource="&obo;CHEBI_38561"/>
        <obo:IAO_0000136 rdf:resource="&obo;CHEBI_46081"/>
    </owl:NamedIndividual>
    


    <!-- http://127.0.0.1:3333/78798 -->

    <owl:NamedIndividual rdf:about="http://127.0.0.1:3333/78798">
        <rdf:type rdf:resource="&obo;DIDEO_00000000"/>
        <rdfs:comment>CredibleMeds</rdfs:comment>
        <obo:IAO_0000136>AMIODARONE</obo:IAO_0000136>
        <obo:IAO_0000136>SIMVASTATIN</obo:IAO_0000136>
        <rdfs:comment>Increased simvastatin/ lovastatin concentrations and risk of myopathy/ rhabdomyolysis</rdfs:comment>
        <rdfs:comment>Inhibition of metabolism of simvastatin/ lovastatin by CYP3A4</rdfs:comment>
        <rdfs:comment>Usually Avoid Consider Alternatives: Preferable statin alternatives include fluvastatin, rosuvastatin, or pravastatin. Predisposing risk factors for rhabdomyolysis include advanced age (&gt;65 years), uncontrolled hypothyroidism, and renal impairment. Monitor: If alternative statins are not appropriate, monitor the patient for evidence of myopathy (muscle pain or weakness) and myoglobinuria (dark urine). The simvastatin dose should not exceed 20 mg/day in combination with amiodarone.</rdfs:comment>
        <rdfs:comment>None</rdfs:comment>
        <obo:IAO_0000136 rdf:resource="&obo;CHEBI_2663"/>
        <obo:IAO_0000136 rdf:resource="&obo;CHEBI_9150"/>
    </owl:NamedIndividual>
    


    <!-- http://127.0.0.1:3333/78810 -->

    <owl:NamedIndividual rdf:about="http://127.0.0.1:3333/78810">
        <rdf:type rdf:resource="&obo;DIDEO_00000000"/>
        <rdfs:comment>None</rdfs:comment>
        <rdfs:comment>Inhibition of simvastatin/ lovastatin metabolism by CYP3A4</rdfs:comment>
        <rdfs:comment>Increased simvastatin/ lovastatin concentrations and risk of myopathy/ rhabdomyolysis</rdfs:comment>
        <obo:IAO_0000136>LOVASTATIN</obo:IAO_0000136>
        <rdfs:comment>CredibleMeds</rdfs:comment>
        <rdfs:comment>Usually Avoid Consider Alternative Antifungal Agents: Terbinafine or ciclopirox nail lacquer would be relatively safer antifungal agents. Consider Alternative Statins: For patients requiring long-term azole antifungal therapy, preferable statin alternatives include fluvastatin, rosuvastatin, or pravastatin. Temporarily Hold Statin Therapy: Temporarily holding the simvastatin/lovastatin during short-term (e.g., 2-week) azole antifungal therapy is a reasonable alternative for patients with stable cardiovascular disease. Monitor: If alternatives are not appropriate, the patient should be monitored for evidence of myopathy (muscle pain or weakness) and myoglobinuria (dark urine).</rdfs:comment>
        <obo:IAO_0000136>KETOCONAZOLE</obo:IAO_0000136>
        <obo:IAO_0000136 rdf:resource="&obo;CHEBI_40303"/>
        <obo:IAO_0000136 rdf:resource="&obo;CHEBI_48339"/>
    </owl:NamedIndividual>
    


    <!-- http://127.0.0.1:3333/78824 -->

    <owl:NamedIndividual rdf:about="http://127.0.0.1:3333/78824">
        <rdf:type rdf:resource="&obo;DIDEO_00000000"/>
        <rdfs:comment>Increased simvastatin/ lovastatin concentrations and risk of myopathy/ rhabdomyolysis</rdfs:comment>
        <rdfs:comment>CredibleMeds</rdfs:comment>
        <rdfs:comment>None</rdfs:comment>
        <obo:IAO_0000136>ITRACONAZOLE</obo:IAO_0000136>
        <rdfs:comment>Usually Avoid Consider Alternative Antifungal Agents: Terbinafine or ciclopirox nail lacquer would be relatively safer antifungal agents. Consider Alternative Statins: For patients requiring long-term azole antifungal therapy, preferable statin alternatives include fluvastatin, rosuvastatin, or pravastatin. Temporarily Hold Statin Therapy: Temporarily holding the simvastatin/lovastatin during short-term (e.g., 2-week) azole antifungal therapy is a reasonable alternative for patients with stable cardiovascular disease. Monitor: If alternatives are not appropriate, the patient should be monitored for evidence of myopathy (muscle pain or weakness) and myoglobinuria (dark urine).</rdfs:comment>
        <rdfs:comment>Inhibition of simvastatin/ lovastatin metabolism by CYP3A4</rdfs:comment>
        <obo:IAO_0000136>SIMVASTATIN</obo:IAO_0000136>
        <obo:IAO_0000136 rdf:resource="&obo;CHEBI_6076"/>
        <obo:IAO_0000136 rdf:resource="&obo;CHEBI_9150"/>
    </owl:NamedIndividual>
    


    <!-- http://127.0.0.1:3333/79559 -->

    <owl:NamedIndividual rdf:about="http://127.0.0.1:3333/79559">
        <rdf:type rdf:resource="&obo;DIDEO_00000000"/>
        <rdfs:comment>The elimination half life of midazolam and triazolam also increased (1.5-2.5 fold) during coadministration with diltiazem.| </rdfs:comment>
        <rdfs:comment>None</rdfs:comment>
        <rdfs:comment>DDI-Corpus-2011</rdfs:comment>
        <obo:IAO_0000136>DILTIAZEM</obo:IAO_0000136>
        <obo:IAO_0000136>TRIAZOLAM</obo:IAO_0000136>
        <obo:IAO_0000136 rdf:resource="&obo;CHEBI_101278"/>
        <obo:IAO_0000136 rdf:resource="&obo;CHEBI_9674"/>
    </owl:NamedIndividual>
    


    <!-- http://127.0.0.1:3333/81264 -->

    <owl:NamedIndividual rdf:about="http://127.0.0.1:3333/81264">
        <rdf:type rdf:resource="&obo;DIDEO_00000000"/>
        <rdfs:comment>None</rdfs:comment>
        <rdfs:comment>The elimination half life of midazolam and triazolam also increased (1.5-2.5 fold) during coadministration with diltiazem.| </rdfs:comment>
        <obo:IAO_0000136>DILTIAZEM</obo:IAO_0000136>
        <rdfs:comment>DDI-Corpus-2013</rdfs:comment>
        <obo:IAO_0000136>TRIAZOLAM</obo:IAO_0000136>
        <rdfs:comment>mechanism</rdfs:comment>
        <obo:IAO_0000136 rdf:resource="&obo;CHEBI_101278"/>
        <obo:IAO_0000136 rdf:resource="&obo;CHEBI_9674"/>
    </owl:NamedIndividual>
    


    <!-- http://127.0.0.1:3333/81642 -->

    <owl:NamedIndividual rdf:about="http://127.0.0.1:3333/81642">
        <rdf:type rdf:resource="&obo;DIDEO_00000000"/>
        <rdfs:comment>NLM-Corpus</rdfs:comment>
        <obo:IAO_0000136>SIMVASTATIN</obo:IAO_0000136>
        <rdfs:comment>Caution_Interaction</rdfs:comment>
        <rdfs:comment>None</rdfs:comment>
        <obo:IAO_0000136>AMIODARONE</obo:IAO_0000136>
        <rdfs:comment>true</rdfs:comment>
        <obo:IAO_0000136 rdf:resource="&obo;CHEBI_2663"/>
        <obo:IAO_0000136 rdf:resource="&obo;CHEBI_9150"/>
    </owl:NamedIndividual>
    


    <!-- http://127.0.0.1:3333/81643 -->

    <owl:NamedIndividual rdf:about="http://127.0.0.1:3333/81643">
        <rdf:type rdf:resource="&obo;DIDEO_00000000"/>
        <rdfs:comment>true</rdfs:comment>
        <obo:IAO_0000136>Simvastatin</obo:IAO_0000136>
        <obo:IAO_0000136>DILTIAZEM</obo:IAO_0000136>
        <rdfs:comment>Caution_Interaction</rdfs:comment>
        <rdfs:comment>NLM-Corpus</rdfs:comment>
        <rdfs:comment>None</rdfs:comment>
        <obo:IAO_0000136 rdf:resource="&obo;CHEBI_101278"/>
        <obo:IAO_0000136 rdf:resource="&obo;CHEBI_9150"/>
    </owl:NamedIndividual>
    


    <!-- http://127.0.0.1:3333/81670 -->

    <owl:NamedIndividual rdf:about="http://127.0.0.1:3333/81670">
        <rdf:type rdf:resource="&obo;DIDEO_00000000"/>
        <obo:IAO_0000136>TRIAZOLAM</obo:IAO_0000136>
        <rdfs:comment>None</rdfs:comment>
        <rdfs:comment>Increase_Interaction</rdfs:comment>
        <rdfs:comment>NLM-Corpus</rdfs:comment>
        <obo:IAO_0000136>DILTIAZEM</obo:IAO_0000136>
        <rdfs:comment>true</rdfs:comment>
        <obo:IAO_0000136 rdf:resource="&obo;CHEBI_101278"/>
        <obo:IAO_0000136 rdf:resource="&obo;CHEBI_9674"/>
    </owl:NamedIndividual>
    


    <!-- http://127.0.0.1:3333/82068 -->

    <owl:NamedIndividual rdf:about="http://127.0.0.1:3333/82068">
        <rdf:type rdf:resource="&obo;DIDEO_00000000"/>
        <rdfs:comment>ONC-HighPriority</rdfs:comment>
        <obo:IAO_0000136>Diltiazem</obo:IAO_0000136>
        <rdfs:comment>None</rdfs:comment>
        <obo:IAO_0000136>Simvastatin</obo:IAO_0000136>
        <obo:IAO_0000136 rdf:resource="&obo;CHEBI_101278"/>
        <obo:IAO_0000136 rdf:resource="&obo;CHEBI_9150"/>
    </owl:NamedIndividual>
    


    <!-- http://127.0.0.1:3333/82210 -->

    <owl:NamedIndividual rdf:about="http://127.0.0.1:3333/82210">
        <rdf:type rdf:resource="&obo;DIDEO_00000000"/>
        <obo:IAO_0000136>Amiodarone</obo:IAO_0000136>
        <rdfs:comment>ONC-HighPriority</rdfs:comment>
        <rdfs:comment>None</rdfs:comment>
        <obo:IAO_0000136>Simvastatin</obo:IAO_0000136>
        <obo:IAO_0000136 rdf:resource="&obo;CHEBI_2663"/>
        <obo:IAO_0000136 rdf:resource="&obo;CHEBI_9150"/>
    </owl:NamedIndividual>
    


    <!-- http://127.0.0.1:3333/82404 -->

    <owl:NamedIndividual rdf:about="http://127.0.0.1:3333/82404">
        <rdf:type rdf:resource="&obo;DIDEO_00000000"/>
        <obo:IAO_0000136>Lovastatin</obo:IAO_0000136>
        <rdfs:comment>ONC-HighPriority</rdfs:comment>
        <obo:IAO_0000136>Ketoconazole</obo:IAO_0000136>
        <rdfs:comment>None</rdfs:comment>
        <obo:IAO_0000136 rdf:resource="&obo;CHEBI_40303"/>
        <obo:IAO_0000136 rdf:resource="&obo;CHEBI_48339"/>
    </owl:NamedIndividual>
    


    <!-- http://127.0.0.1:3333/82988 -->

    <owl:NamedIndividual rdf:about="http://127.0.0.1:3333/82988">
        <rdf:type rdf:resource="&obo;DIDEO_00000000"/>
        <obo:IAO_0000136>Itraconazole</obo:IAO_0000136>
        <rdfs:comment>None</rdfs:comment>
        <rdfs:comment>ONC-HighPriority</rdfs:comment>
        <obo:IAO_0000136>Simvastatin</obo:IAO_0000136>
        <obo:IAO_0000136 rdf:resource="&obo;CHEBI_6076"/>
        <obo:IAO_0000136 rdf:resource="&obo;CHEBI_9150"/>
    </owl:NamedIndividual>
    


    <!-- http://127.0.0.1:3333/89138 -->

    <owl:NamedIndividual rdf:about="http://127.0.0.1:3333/89138">
        <rdf:type rdf:resource="&obo;DIDEO_00000000"/>
        <obo:IAO_0000136>Diltiazem</obo:IAO_0000136>
        <rdfs:comment> </rdfs:comment>
        <obo:IAO_0000136>Triazolam</obo:IAO_0000136>
        <rdfs:comment>N</rdfs:comment>
        <rdfs:comment>None</rdfs:comment>
        <rdfs:comment>P</rdfs:comment>
        <rdfs:comment>OSCAR</rdfs:comment>
        <obo:IAO_0000136 rdf:resource="&obo;CHEBI_101278"/>
        <obo:IAO_0000136 rdf:resource="&obo;CHEBI_9674"/>
    </owl:NamedIndividual>
    


    <!-- http://purl.obolibrary.org/obo/CHEBI_101278 -->

    <owl:NamedIndividual rdf:about="&obo;CHEBI_101278">
        <rdf:type rdf:resource="&obo;CHEBI_24431"/>
        <rdfs:label xml:lang="en">diltiazem</rdfs:label>
    </owl:NamedIndividual>
    


    <!-- http://purl.obolibrary.org/obo/CHEBI_2663 -->

    <owl:NamedIndividual rdf:about="&obo;CHEBI_2663">
        <rdf:type rdf:resource="&obo;CHEBI_24431"/>
        <rdfs:label xml:lang="en">amiodarone</rdfs:label>
    </owl:NamedIndividual>
    


    <!-- http://purl.obolibrary.org/obo/CHEBI_38545 -->

    <owl:NamedIndividual rdf:about="&obo;CHEBI_38545">
        <rdf:type rdf:resource="&obo;CHEBI_24431"/>
        <rdfs:label xml:lang="en">rosuvastatin</rdfs:label>
    </owl:NamedIndividual>
    


    <!-- http://purl.obolibrary.org/obo/CHEBI_38561 -->

    <owl:NamedIndividual rdf:about="&obo;CHEBI_38561">
        <rdf:type rdf:resource="&obo;CHEBI_24431"/>
        <rdfs:label xml:lang="en">fluvastatin</rdfs:label>
    </owl:NamedIndividual>
    


    <!-- http://purl.obolibrary.org/obo/CHEBI_39548 -->

    <owl:NamedIndividual rdf:about="&obo;CHEBI_39548">
        <rdf:type rdf:resource="&obo;CHEBI_24431"/>
        <rdfs:label xml:lang="en">atorvastatin</rdfs:label>
    </owl:NamedIndividual>
    


    <!-- http://purl.obolibrary.org/obo/CHEBI_40303 -->

    <owl:NamedIndividual rdf:about="&obo;CHEBI_40303">
        <rdf:type rdf:resource="&obo;CHEBI_24431"/>
        <rdfs:label xml:lang="en">lovastatin</rdfs:label>
    </owl:NamedIndividual>
    


    <!-- http://purl.obolibrary.org/obo/CHEBI_46081 -->

    <owl:NamedIndividual rdf:about="&obo;CHEBI_46081">
        <rdf:type rdf:resource="&obo;CHEBI_24431"/>
        <rdfs:label xml:lang="en">fluconazole</rdfs:label>
    </owl:NamedIndividual>
    


    <!-- http://purl.obolibrary.org/obo/CHEBI_48339 -->

    <owl:NamedIndividual rdf:about="&obo;CHEBI_48339">
        <rdf:type rdf:resource="&obo;CHEBI_24431"/>
        <rdfs:label xml:lang="en">ketoconazole</rdfs:label>
    </owl:NamedIndividual>
    


    <!-- http://purl.obolibrary.org/obo/CHEBI_6076 -->

    <owl:NamedIndividual rdf:about="&obo;CHEBI_6076">
        <rdf:type rdf:resource="&obo;CHEBI_24431"/>
        <rdfs:label xml:lang="en">itraconazole</rdfs:label>
    </owl:NamedIndividual>
    


    <!-- http://purl.obolibrary.org/obo/CHEBI_9150 -->

    <owl:NamedIndividual rdf:about="&obo;CHEBI_9150">
        <rdf:type rdf:resource="&obo;CHEBI_24431"/>
        <rdfs:label xml:lang="en">simvastatin</rdfs:label>
    </owl:NamedIndividual>
    


    <!-- http://purl.obolibrary.org/obo/CHEBI_9674 -->

    <owl:NamedIndividual rdf:about="&obo;CHEBI_9674">
        <rdf:type rdf:resource="&obo;CHEBI_24431"/>
        <rdfs:label xml:lang="en">triazolam</rdfs:label>
    </owl:NamedIndividual>
</rdf:RDF>



<!-- Generated by the OWL API (version 3.5.0) http://owlapi.sourceforge.net -->

